Health Problems 

Mesothelioma trial suggests immunotherapy as an alternative to chemotherapy

09/30/2019 alternative, an, as, chemotherapy, immunotherapy, Mesothelioma, suggests, to, Trial

Patients with mesothelioma may gain similar benefit from immunotherapy as chemotherapy, and good responders may provide important clues to novel

Read more

Health News 

New leukaemia drug produces ‘very positive results’ in a trial

09/02/2019 a, Drug, in, New leukaemia, positive, produces, results, Trial, Very

New leukaemia therapy produces ‘very positive results’ in a trial with five out of 14 ‘incurable’ patients disease-free 2.5 years

Read more

Health Problems 

Researchers say pioneering emergency eye care trial leads to quicker treatment times

08/07/2019 care, emergency, eye, leads, pioneering, quicker, Researchers, say, times, to, Treatment, Trial

A trial virtual emergency consultation programme for eye patients has led to quicker treatment times and removed the need for

Read more

Health News 

Male contraceptive trial ‘is a chance to take responsibility’

06/25/2019 a, chance, contraceptive, Is, male, Responsibility, take, to, Trial

PhD student enrolled in a trial of male contraceptive gel that is rubbed into the shoulders says it is an

Read more

Health Problems 

Drugs to prevent stroke and dementia show promise in early trial

04/25/2019 and, Dementia, Drugs, early, in, prevent, promise, show, Stroke, to, Trial

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain

Read more

Medications 

Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH

04/18/2019 2, Albireo, Announces, Clearance, Commence, Elobixibat, FDA, for, IND, NAFLD/NASH, of, Phase, The, to, Treatment, Trial

BOSTON, April 11, 2019 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing

Read more

Medications 

Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata

01/05/2019 2b/3, Alopecia, an, Areata, Clinical, for, Inhibitor, Initiates, JAK3, Moderate, of, Oral, Patients, PF-06651600, Pfizer, Phase, Severe, The, to, Treatment, Trial, with

January 3, 2019 — Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase 2b/3 clinical trial for its

Read more